Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Reduce the dose of sulphonylureas when adding DPP-4 inhibitor treatment in patients with type 2 diabetes, study warns.
Read More »What You Need To Know When Adding A DPP-4 Inhibitor
No Higher Risk of Heart Failure with DPP-4 Inhibitors
Type 2 patients who used saxagliptin or sitagliptin had similar risks for heart failure as those who received other anti-hyperglycemic agents, according to a retrospective cohort study.
Read More »Januvia for High Risk CVD Patients is Safe
A secondary analysis of the TECOS trial affirms sitagliptin does not increase heart failure risk for patients with type 2 diabetes.
Read More »FDA Warns of Increased Heart-Failure Risk With Two New Diabetes Drugs
New alert issued for type 2 patients taking saxagliptin (Onglyza, AstraZeneca) and alogliptin (Nesina, Takeda).
Read More »Alogliptin Prevents the Progression of Atherosclerosis in Type 2 Diabetes Patients
New study suggests possible role for DPP-4 inhibitor in reducing CVD risk.
Read More »Pancreatic Cancer Not Associated with Incretin Drugs
Study results indicate that risk increased similarly for all glucose lowering agents.
Read More »Dapagliflozin Added to Saxagliptin Plus Metformin in Type 2 Diabetes
New study suggests triple therapy improves glycemic control.
Read More »Once-Weekly Dosing DDP-4 Inhibitor Effectiveness in Japanese Diabetes Patients
Oral med approved by the Japanese Pharmaceuticals and Medical Devices Agency (PDMA) for type 2 treatment.
Read More »Fewer Adverse Effects Observed When Adding Dipeptidyl Peptidase-4 Inhibitors to Metformin Therapy
Combination does not alter myocardial infarction, hospitalization risks.
Read More »Christophe Arbet-Engels, MD, Q9: Diabetes Drugs in the Pipeline
Dr. Christophe Arbet-Engels talks about some of the diabetes drugs in Boehringer Ingelheim’s pipeline including several compounds with liagliptin which BI is continuing to study and expand their knowledge of. They have looked at data in the past on African Americans and are now examining data of the drug’s efficacy in …
Read More »